Skip to main content
. 2022 Mar 25;12:811783. doi: 10.3389/fonc.2022.811783

Figure 5.

Figure 5

The in vitro therapeutical effects on ovarian cancer HO8910 cells intervened by the combined DDP chemotherapy, CD44-shRNA gene therapy, and MFH. (A) The cell proliferation inhibition rate of each group tested by MTT. **p < 0.01 vs. that of negative control group. (B) The cell apoptosis of each group analyzed by flow cytometry (a, negative control group; b, DDP group; c, DDP/CD44-shRNA group; d, PEG-MZF-NPs/MFH group; e, CD44-shRNA/MFH group; f, DDP/MFH group; g, DDP/CD44-shRNA/MFH group; h, quantitative statistical results). (C) Results of HO8910 cells’ invasion experiment in different experimental groups (a, negative control group; b, DDP group; c, DDP/CD44-shRNA group; d, PEG-MZF-NPs/MFH group; e, CD44-shRNA/MFH group; f, DDP/MFH group; g, DDP/CD44-shRNA/MFH group; h, quantitative statistical results). (D) VEGF, survivin, Bcl-2, Bcl-xl, cleaved caspase-3, and cleaved caspase-9 protein expression in different groups. *p < 0.05, ***p < 0.001 v.s. negative control.